Fairmount Funds Management LLC
CIK 0001802528 · WEST CONSHOHOCKEN, PA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$1.51B
2026 Q2
Positions
12
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
97.6%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
ORKA
ORUKA THERAPEUTICS INC
23.3%
DNTH
DIANTHUS THERAPEUTICS INC
16.3%
36322Q206
DAMORA THERAPEUTICS INC
15.0%
COGT
COGENT BIOSCIENCES INC
14.1%
JBIO
JADE BIOSCIENCES INC
6.7%
ELVN
ENLIVEN THERAPEUTICS INC
6.2%
VRDN
VIRIDIAN THERAPEUTICS INC
6.2%
ZBIO
ZENAS BIOPHARMA INC
4.0%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.